Sanofi says good results from flu vaccine with mRNA booster study
A Sanofi logo is seen during the company’s annual results news conference in Paris, France, February 6, 2020. REUTERS FILE PHOTO
PARIS — French healthcare company Sanofi said on Wednesday that it had found positive results from the first study into a high-dose influenza vaccine with a COVID-19 mRNA booster.
Sanofi said the interim results from the study of Sanofi’s Fluzone High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose showed the vaccines had similar immunogenicity responses and a similar safety and tolerability profile.
“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this
